These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32569019)

  • 41. Breastfeeding and Sexual Activity and Sexual Quality in Postpartum Women.
    Alp Yılmaz F; Şener Taplak A; Polat S
    Breastfeed Med; 2019 Oct; 14(8):587-591. PubMed ID: 31298557
    [No Abstract]   [Full Text] [Related]  

  • 42. Vaginal atrophy across the menopausal age: results from the ANGEL study.
    Cagnacci A; Xholli A; Sclauzero M; Venier M; Palma F; Gambacciani M;
    Climacteric; 2019 Feb; 22(1):85-89. PubMed ID: 30601037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genitourinary syndrome of lactation: a new perspective on postpartum and lactation-related genitourinary symptoms.
    Perelmuter S; Burns R; Shearer K; Grant R; Soogoor A; Jun S; Meurer JA; Krapf J; Rubin R
    Sex Med Rev; 2024 Jun; 12(3):279-287. PubMed ID: 38757214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
    Vicariotto F; Raichi M
    Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
    Bouchard C; Labrie F; Archer DF; Portman DJ; Koltun W; Elfassi É; Grainger DA; Ayotte N; Cooper TA; Martens M; Waldbaum AS; Labrie C; Côté I; Lavoie L; Martel C; Balser J;
    Climacteric; 2015; 18(4):590-607. PubMed ID: 25511551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resumption of intercourse, self-reported decline in sexual intercourse and dyspareunia in women by mode of birth: A prospective follow-up study.
    Triviño-Juárez JM; Romero-Ayuso D; Nieto-Pereda B; Forjaz MJ; Oliver-Barrecheguren C; Mellizo-Díaz S; Avilés-Gámez B; Arruti-Sevilla B; Criado-Álvarez JJ; Soto-Lucía C; Plá-Mestre R
    J Adv Nurs; 2018 Mar; 74(3):637-650. PubMed ID: 28981973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ospemifene in the treatment of vulvovaginal atrophy.
    Barnes KN; Pearce EF; Yancey AM; Forinash AB
    Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN; Clinard VB; Woodis CB
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vulvovaginal Discomfort Is Common in Both Premenopausal and Postmenopausal Women.
    Watson LJ; James KE; Hatoum Moeller IJ; Mitchell CM
    J Low Genit Tract Dis; 2019 Apr; 23(2):164-169. PubMed ID: 30741753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy.
    Di Donato V; Schiavi MC; Iacobelli V; D'oria O; Kontopantelis E; Simoncini T; Muzii L; Benedetti Panici P
    Maturitas; 2019 Mar; 121():86-92. PubMed ID: 30509753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Macro-regional variation in attitudes toward and experiences of vulvar and vaginal atrophy among Italian post-menopausal women: a post hoc analysis of REVIVE survey data.
    Nappi RE; Particco M; Biglia N; Cagnacci A; Di Carlo C; Luisi S; Paoletti AM
    Gynecol Endocrinol; 2017 May; 33(5):389-394. PubMed ID: 28277131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women.
    Nappi RE; Kotek M; Brešt'anský A; Giordan N; Tramentozzi E
    Climacteric; 2020 Oct; 23(5):519-524. PubMed ID: 32396754
    [No Abstract]   [Full Text] [Related]  

  • 54. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
    J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations.
    Lev-Sagie A
    Clin Obstet Gynecol; 2015 Sep; 58(3):476-91. PubMed ID: 26125962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
    Simon JA; Archer DF; Kagan R; Bernick B; Graham S; Constantine GD; Mirkin S
    Menopause; 2017 Sep; 24(9):1003-1010. PubMed ID: 28419068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions.
    Palacios S; Cancelo MJ; Castelo Branco C; Llaneza P; Molero F; Borrego RS
    Climacteric; 2017 Feb; 20(1):55-61. PubMed ID: 28042734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
    Edwards D; Panay N
    Climacteric; 2016 Apr; 19(2):151-61. PubMed ID: 26707589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
    Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
    Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.